A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee
Background and Objective: New pharmacovigilance legislation in the European Union has underlined the importance of signal management, giving the European Medicines Agency’s newly established Pharmacovigilance Risk Assessment Committee (PRAC) the mandate to oversee all aspects of the use of medicinal products including detection, assessment, minimization, and communication relating to the risk of adverse reactions. In this study, we describe the signals as brought to the PRAC during the first 18 months of its operation and the ensuing regulatory actions.Methods: Data were collected from publicly available sources, for the period July 2012–December 2013, classified according to predefined rules, and described using the appropriate descriptive statistics. Suspected adverse drug reactions were categorized into the Medical Dictionary for Regulatory Affairs and drug names were mapped to the Anatomical Therapeutic Chemical codes.Results: During the study period, 125 signals concerning 96 medicinal products were discussed by the PRAC. The majority of signals were triggered by spontaneous reports (62 %) and the median drug age (since marketing authorization) for drugs that prompted a signal was 12 years, significantly less compared with drugs that had no signal within the same period (20 years). The mean time until a decision was reached by the PRAC was 75 days (median 30 days, range 0–273) with 43 % of all decisions taken during the first meeting. The decisions to start a referral and to send a direct healthcare professional communication took the least amount of time [54 days (median 27 days, range 0–186) and 51 days (median 0 days, range 0–153)].Conclusions: The importance of spontaneous reporting in signal detection and monitoring of safety issues throughout the entire life cycle of a medicinal product is confirmed in this study. The amount of time a drug has been on the market is correlated with the number of signals detected. The PRAC decision-making process seems efficient particularly with respect to serious concerns; its role in improving signal prioritization and real-time signal management will be further clarified in its subsequent years of operation.
|Persistent URL||dx.doi.org/10.1007/s40264-014-0240-1, hdl.handle.net/1765/88945|
Păcurariu, A.C, Coloma, P.M, van Haren, A, Genov, G, Sturkenboom, M.C.J.M, & Straus, S.M.J.M. (2014). A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee. Drug Safety, 37(12), 1059–1066. doi:10.1007/s40264-014-0240-1